ID   RPC-9
AC   CVCL_B263
SY   RPC9
DR   cancercelllines; CVCL_B263
DR   Cosmic; 1083085
DR   Wikidata; Q54951132
RX   PubMed=17699786;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 18
//
RX   PubMed=17699786; DOI=10.1158/0008-5472.CAN-07-0681;
RA   Ogino A., Kitao H., Hirano S., Uchida A., Ishiai M., Kozuki T.,
RA   Takigawa N., Takata M., Kiura K., Tanimoto M.;
RT   "Emergence of epidermal growth factor receptor T790M mutation during
RT   chronic exposure to gefitinib in a non small cell lung cancer cell
RT   line.";
RL   Cancer Res. 67:7807-7814(2007).
//